Skip to main content
Signal8

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

$INCYPress releaseNov 10, 2026, 7:00 AM ETRead the release

Incyte entered a clinical collaboration with Natera for a Phase II study of INCA33890, its investigational bispecific immunotherapy, in stage 2/3 colorectal cancer patients who completed surgery and adjuvant chemotherapy. Patients will undergo longitudinal Signatera MRD testing for up to 12 months, and those who test MRD-positive without radiographic disease may enroll and receive treatment — a treatment-on-MRD (TOMR) design.

Key figures

Drug Name
INCA33890
Phase Of Trial
Phase II
Trial indication
stage 2/3 colorectal cancer after surgery and adjuvant chemotherapy
Signatera testing duration
up to 12 months

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer — AI Analysis | Signal8